Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy
Open Access
- 31 July 2026
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (8) , e70308
Abstract
Respiratory syncytial virus (RSV) infection can result in a range of disease severity from mild upper respiratory tract symptoms to lower respiratory tract illness, with clinical manifestations dependent on age, co‐morbidities, and immune status. At present, there is no antiviral approved for adults with RSV disease, and only one treatment option with limited utilization is available for pediatric patients. While several RSV antiviral candidates have demonstrated virological efficacy in healthy adult challenge studies, to date they have subsequently failed to show efficacy in patients. Mechanistically understanding the translation of efficacy from preclinical to challenge to patient studies is essential in addressing this unmet medical need in children and adults with RSV disease. This work uses a quantitative systems pharmacology (QSP) approach to mathematically represent the underlying pathophysiology of RSV infection to simulate and predict the effects of investigational direct acting RSV antiviral therapeutics. We developed virtual populations that capture viral load dynamics in viral challenge studies, where the participants are healthy adult volunteers, upon treatment with the F‐protein inhibitor sisunatovir and the N‐protein inhibitor zelicapavir. Due to underlying differences in dynamics between key populations, we also developed a pediatric patient virtual population to match the results from the zelicapavir pediatric Phase 2 study. This work projects that for a minimum coverage > 1× free EC 90 at C min , a treatment window of 5 to 7 days post‐symptom onset is feasible for observing virological efficacy in pediatric patients and may lead to potential success in a phase 3 pivotal RSV antiviral drug trial.Keywords
This publication has 40 references indexed in Scilit:
- Role of human infection challenge studies (HICs) in drug development for respiratory syncytial virus (RSV): systematic review and meta-analysisEBioMedicine, 2025
- CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial VirusPediatric Drugs, 2024
- A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventionsnpj Systems Biology and Applications, 2023
- The rate of viral transfer between upper and lower respiratory tracts determines RSV illness durationJournal of Mathematical Biology, 2019
- Modeling of fusion inhibitor treatment of RSV in African green monkeysJournal of Theoretical Biology, 2018
- Improving the generation and selection of virtual populations in quantitative systems pharmacology modelsProgress in Biophysics and Molecular Biology, 2018
- A quantitative assessment of dynamical differences of RSV infections in vitro and in vivoVirology, 2018
- Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infantsPediatric Research, 2017
- Plasma Protein Binding of Challenging CompoundsJournal of Pharmaceutical Sciences, 2015
- Incubation periods of acute respiratory viral infections: a systematic reviewThe Lancet Infectious Diseases, 2009